Last reviewed 2026-04-23 · How we verify

LY4065967

LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.

LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for FGFR-altered solid tumors (Phase 2 development).

At a glance

Mechanism of action

The drug targets fibroblast growth factor receptors, which are frequently dysregulated in various cancers through mutations, amplifications, or translocations. By inhibiting FGFR kinase activity, LY4065967 suppresses downstream signaling pathways that drive cell proliferation and survival in FGFR-dependent tumors. This mechanism is particularly relevant in cancers with FGFR alterations, including certain lung, gastric, and other solid tumors.

Approved indications

• FGFR-altered solid tumors (Phase 2 development)

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea

Key clinical trials

• A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain (PHASE2)
• A Study of [14C]-LY4065967 in Healthy Participants (PHASE1)
• A Study of LY4065967 in Healthy Japanese Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LY4065967 CI brief — competitive landscape report
• LY4065967 updates RSS · CI watch RSS
• Eli Lilly and Company portfolio CI